Fig 1.
MP characterization by flow cytometry.
A: Acquisition gate (H) was based on forward- and side-scatter values of 0.9 mm-large calibration beads; B: autofluorescence was determined using isotopic control (IgG-PE); C: platelet-derived MPs or D: erythrocyte-derived MPs were labelled with FITC-annexin-V (FL1) and PE-conjugated monoclonal antibodies directed against CD41 or CD235a, respectively.
Table 1.
Biological and clinical characteristics of the SCD studied patients.
Table 2.
Cellular origins and blood MP concentrations of SCA and HbSC patients.
Fig 2.
Comparison of RBC- and PLT-derived MP characteristics between SCA and HbSC patients.
A: mean fluorescence intensity of annexin V; B: mean forward scatter index. The value distributions are represented as box and whiskers (min to max). ****: p < 10−4.
Fig 3.
Comparison of total MP concentrations between not HC-treated SCA and HbSC patients classified according to the occurrence of VOC, ACS and abnormal TRJV.
A: Not HC-treated SCA children classified according to VOC, ACS and TRJV ≥ 2.5 m/s occurrences respectively. B: HbSC children classified according to VOC ACS and TRJV ≥ 2.5 m/s occurrences respectively. Blood total MP concentrations are represented as median with interquartile range.
Table 3.
Correlation between MP concentrations and markers of hemolysis/anemia in SCD patients.